Literature DB >> 1360195

Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group.

S T DeKosky1, R E Harbaugh, F A Schmitt, R A Bakay, H C Chui, D S Knopman, T M Reeder, A G Shetter, H J Senter, W R Markesbery.   

Abstract

Neurochemical assessments were performed on biopsy samples taken from the right frontal lobe of patients diagnosed with Alzheimer's disease (AD), before the implantation of a ventricular catheter and pump assembly for the infusion of bethanechol chloride as an experimental therapy. The pathologically diagnosed patients with AD (n = 35; mean age, 67 +/- 1.5 yr) were compared with a group of samples from normal age-equivalent autopsied controls (n = 22; mean age, 68 +/- 2 yr) and autopsied AD brains (n = 11; mean age, 73 +/- 2 yr). Samples were assayed for choline acetyltransferase (ChAT), acetylcholinesterase, binding to [3H]quinuclidinyl benzilate as an index of total muscarinic cholinergic binding, and [3H]pirenzepine binding as an index of M1 cholinergic receptor subtype binding. Mean levels of ChAT activity were decreased in the biopsied patients to 36% of age-matched autopsied controls. The loss of ChAT activity correlated significantly with the Mini-Mental State Examination, an index of global cognitive function. Mean ChAT activity in autopsied AD cortex was further decreased compared with controls, indicating continuous decline through the course of the disease. Acetylcholinesterase followed a similar, less dramatic decline. No differences were found in [3H]quinuclidinyl benzilate binding or [3H]pirenzepine binding between biopsied and autopsied controls. Neuritic plaque counts did not correlate with either the Mini-Mental State Examination or ChAT activity in the biopsy specimens.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360195     DOI: 10.1002/ana.410320505

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  55 in total

1.  Tacrine for Alzheimer's disease. Costs and benefits.

Authors:  D Knopman
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

2.  Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease.

Authors:  Sylvia E Perez; Damianka P Getova; Bin He; Scott E Counts; Changiz Geula; Laurent Desire; Severine Coutadeur; Helene Peillon; Stephen D Ginsberg; Elliott J Mufson
Journal:  Am J Pathol       Date:  2011-12-03       Impact factor: 4.307

3.  Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors.

Authors:  J Winkler; G A Ramirez; L J Thal; J J Waite
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 4.  On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease.

Authors:  Simona Capsoni; Antonino Cattaneo
Journal:  Cell Mol Neurobiol       Date:  2006-08-31       Impact factor: 5.046

5.  Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting.

Authors:  R Bech-Azeddine; P Høgh; M Juhler; F Gjerris; G Waldemar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

Review 6.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

7.  Leptin signaling and Alzheimer's disease.

Authors:  Gurdeep Marwarha; Othman Ghribi
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

8.  MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD.

Authors:  S George; E J Mufson; S Leurgans; R C Shah; C Ferrari; L deToledo-Morrell
Journal:  Neurobiol Aging       Date:  2009-12-14       Impact factor: 4.673

9.  Trans-synaptic stimulation of cortical acetylcholine release after partial 192 IgG-saporin-induced loss of cortical cholinergic afferents.

Authors:  J Fadel; H Moore; M Sarter; J P Bruno
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

Review 10.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.